nystatin-a1 and Leishmaniasis--Cutaneous

nystatin-a1 has been researched along with Leishmaniasis--Cutaneous* in 1 studies

Other Studies

1 other study(ies) available for nystatin-a1 and Leishmaniasis--Cutaneous

ArticleYear
Assessing nystatin cream treatment efficacy against Leishmania (L.) amazonensis infection in BALB/c model.
    Experimental parasitology, 2023, Volume: 250

    The current scenario for cutaneous leishmaniasis treatment includes the use of first and second-choice drugs, both therapeutic strategies presenting several adverse effects and being related to an increment of treatment-refractory parasite strains. These facts encourage the search for new treatment approaches, including repositioning drugs, such as nystatin. Although in vitro assays show that this polyene macrolide compound has leishmanicidal activity, no in vivo evidence for a similar activity has been shown so far for the commercial nystatin cream formulation. This work assessed the effects of nystatin cream (25,000 IU/g) administered on mice in an amount to completely cover the paw surface of BALB/c mice infected with Leishmania (L.) amazonensis once a day, until a total of up to 20 doses. The data presented herein points to unequivocal evidence that treatment with this formulation causes a statistically significant reduction of swelling/edema in mice paws when compared to animal groups not submitted to this treatment regimen after the fourth week of infection: lesion sizes at the sixth (p = 0.0159), seventh (p = 0.0079) and eighth (p = 0.0079) week. Furthermore, swelling/edema reduction relates to a decrease in parasite load in the footpad (∼48%) and in draining lymph nodes (∼68%) at eight weeks post-infection. This is the first report of the effectiveness of nystatin cream used as a topical treatment in BALB/c model for cutaneous leishmaniasis.

    Topics: Animals; Edema; Leishmania; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Nystatin; Treatment Outcome

2023